Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Next-generation sequencing : proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma. / Rieneck, Klaus; Bak, Mads; Jønson, Lars; Clausen, Frederik Banch; Krog, Grethe Risum; Tommerup, Niels; Nielsen, Leif Kofoed; Hedegaard, Morten; Dziegiel, Morten Hanefeld.

In: Transfusion, Vol. 53, No. 11 Suppl 2, 11.2013, p. 2892-2898.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Rieneck, K, Bak, M, Jønson, L, Clausen, FB, Krog, GR, Tommerup, N, Nielsen, LK, Hedegaard, M & Dziegiel, MH 2013, 'Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma', Transfusion, vol. 53, no. 11 Suppl 2, pp. 2892-2898. https://doi.org/10.1111/trf.12172

APA

Rieneck, K., Bak, M., Jønson, L., Clausen, F. B., Krog, G. R., Tommerup, N., Nielsen, L. K., Hedegaard, M., & Dziegiel, M. H. (2013). Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma. Transfusion, 53(11 Suppl 2), 2892-2898. https://doi.org/10.1111/trf.12172

Vancouver

Rieneck K, Bak M, Jønson L, Clausen FB, Krog GR, Tommerup N et al. Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma. Transfusion. 2013 Nov;53(11 Suppl 2):2892-2898. https://doi.org/10.1111/trf.12172

Author

Rieneck, Klaus ; Bak, Mads ; Jønson, Lars ; Clausen, Frederik Banch ; Krog, Grethe Risum ; Tommerup, Niels ; Nielsen, Leif Kofoed ; Hedegaard, Morten ; Dziegiel, Morten Hanefeld. / Next-generation sequencing : proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma. In: Transfusion. 2013 ; Vol. 53, No. 11 Suppl 2. pp. 2892-2898.

Bibtex

@article{291647ee25904c04b79b60d51f66a61a,
title = "Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma",
abstract = "BACKGROUND: Maternal immunization against KEL1 of the Kell blood group system can have serious adverse consequences for the fetus as well as the newborn baby. Therefore, it is important to determine the phenotype of the fetus to predict whether it is at risk. We present data that show the feasibility of predicting the fetal KEL1 phenotype using next-generation sequencing (NGS) technology. STUDY DESIGN AND METHODS: The KEL1/2 single-nucleotide polymorphism was polymerase chain reaction (PCR) amplified with one adjoining base, and the PCR product was sequenced using a genome analyzer (GAIIx, Illumina); several millions of PCR sequences were analyzed. RESULTS: The results demonstrated the feasibility of diagnosing the fetal KEL1 or KEL2 blood group from cell-free DNA purified from maternal plasma. CONCLUSION: This method requires only one primer pair, and the large amount of sequence information obtained allows well for statistical analysis of the data. This general approach can be integrated into current laboratory practice and has numerous applications. Besides DNA-based predictions of blood group phenotypes, platelet phenotypes, or sickle cell anemia, and the determination of zygosity, various conditions of chimerism could also be examined using this approach. To our knowledge, this is the first report focused on antenatal blood group determination using NGS.",
author = "Klaus Rieneck and Mads Bak and Lars J{\o}nson and Clausen, {Frederik Banch} and Krog, {Grethe Risum} and Niels Tommerup and Nielsen, {Leif Kofoed} and Morten Hedegaard and Dziegiel, {Morten Hanefeld}",
note = "{\textcopyright} 2013 Department of Clinical Immunology, University Hospital Copenhagen. Transfusion {\textcopyright} 2013 American Association of Blood Banks.",
year = "2013",
month = nov,
doi = "10.1111/trf.12172",
language = "English",
volume = "53",
pages = "2892--2898",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "11 Suppl 2",

}

RIS

TY - JOUR

T1 - Next-generation sequencing

T2 - proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma

AU - Rieneck, Klaus

AU - Bak, Mads

AU - Jønson, Lars

AU - Clausen, Frederik Banch

AU - Krog, Grethe Risum

AU - Tommerup, Niels

AU - Nielsen, Leif Kofoed

AU - Hedegaard, Morten

AU - Dziegiel, Morten Hanefeld

N1 - © 2013 Department of Clinical Immunology, University Hospital Copenhagen. Transfusion © 2013 American Association of Blood Banks.

PY - 2013/11

Y1 - 2013/11

N2 - BACKGROUND: Maternal immunization against KEL1 of the Kell blood group system can have serious adverse consequences for the fetus as well as the newborn baby. Therefore, it is important to determine the phenotype of the fetus to predict whether it is at risk. We present data that show the feasibility of predicting the fetal KEL1 phenotype using next-generation sequencing (NGS) technology. STUDY DESIGN AND METHODS: The KEL1/2 single-nucleotide polymorphism was polymerase chain reaction (PCR) amplified with one adjoining base, and the PCR product was sequenced using a genome analyzer (GAIIx, Illumina); several millions of PCR sequences were analyzed. RESULTS: The results demonstrated the feasibility of diagnosing the fetal KEL1 or KEL2 blood group from cell-free DNA purified from maternal plasma. CONCLUSION: This method requires only one primer pair, and the large amount of sequence information obtained allows well for statistical analysis of the data. This general approach can be integrated into current laboratory practice and has numerous applications. Besides DNA-based predictions of blood group phenotypes, platelet phenotypes, or sickle cell anemia, and the determination of zygosity, various conditions of chimerism could also be examined using this approach. To our knowledge, this is the first report focused on antenatal blood group determination using NGS.

AB - BACKGROUND: Maternal immunization against KEL1 of the Kell blood group system can have serious adverse consequences for the fetus as well as the newborn baby. Therefore, it is important to determine the phenotype of the fetus to predict whether it is at risk. We present data that show the feasibility of predicting the fetal KEL1 phenotype using next-generation sequencing (NGS) technology. STUDY DESIGN AND METHODS: The KEL1/2 single-nucleotide polymorphism was polymerase chain reaction (PCR) amplified with one adjoining base, and the PCR product was sequenced using a genome analyzer (GAIIx, Illumina); several millions of PCR sequences were analyzed. RESULTS: The results demonstrated the feasibility of diagnosing the fetal KEL1 or KEL2 blood group from cell-free DNA purified from maternal plasma. CONCLUSION: This method requires only one primer pair, and the large amount of sequence information obtained allows well for statistical analysis of the data. This general approach can be integrated into current laboratory practice and has numerous applications. Besides DNA-based predictions of blood group phenotypes, platelet phenotypes, or sickle cell anemia, and the determination of zygosity, various conditions of chimerism could also be examined using this approach. To our knowledge, this is the first report focused on antenatal blood group determination using NGS.

U2 - 10.1111/trf.12172

DO - 10.1111/trf.12172

M3 - Journal article

C2 - 23550721

VL - 53

SP - 2892

EP - 2898

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 11 Suppl 2

ER -

ID: 47454774